Searchable abstracts of presentations at key conferences in endocrinology

ea0029p163 | Bone & Osteoporosis | ICEECE2012

Effect of alendronate on bone mineral density in primary hyperparathyroidism

Szymczak J. , Bohdanowicz-Pawlak A. , Jakubowska J.

Background: Bisphosphonates are capable of suppressing parathormone (PTH)-mediated bone resorption and can be used as an adjunct treatment in acute hypercalcemia. We investigated the effects of oral alendronate on bone mineral density (BMD) and biochemical markers of calcium and bone metabolism in patients with primary hyperparathyroidism (PHPT).Methods: Twenty-six patients aged 58.5±13.9 years with confirmed PHPT were treated with alendronate (70 m...

ea0073aep842 | Late Breaking | ECE2021

The first comprehensive study of the clinical response of a cohort of acromegalic patients with somatostatin responsive headache

Sonia Kaniuka-Jakubowska , J Levy Miles , Pal Aparna , Abeyaratne Dayakshi , Drake William , Kyriakakis Nikolaos , D Murray Robert , M Orme Steve , Gohil Shailesh , Brook Antonia , Leese Graham , Márta Korbonits , Wass John

It is known that acromegaly may be associated with headache as a significant co-morbidity. Amongst all acromegaly headache patients, there is a unique group with specific types of severe headache that fail to improve despite acromegaly therapy and are resistant to conventional analgesics, however, immediately respond to subcutaneous short-acting (SA) somatostatin analogue (SSA) treatment. We have surveyed 8 tertiary specialist UK centres and identified 18 patients (6 females) ...